Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H16N2O4S |
Molecular Weight | 296.342 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NS(=O)(=O)CCN1C(=O)C2=C(C=CC=C2)C1=O
InChI
InChIKey=NZKNHIQZWSVJGP-UHFFFAOYSA-N
InChI=1S/C13H16N2O4S/c1-9(2)14-20(18,19)8-7-15-12(16)10-5-3-4-6-11(10)13(15)17/h3-6,9,14H,7-8H2,1-2H3
Taltrimide, a taurine derivative that was developed as an anticonvulsive agent. Taltrimide strongly inhibits the sodium-independent binding of taurine to synaptic membranes of the brain and it does not appear to bind to GABAA and benzodiazepine receptor. The drug was studied in phase II clinical trial Finland as an anticonvulsant agent to treat epilepsy. However, the further development of this drug was discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The anticonvulsive actions of two lipophilic taurine derivatives. | 1985 |
|
Effects of the anticonvulsant taurine derivative, taltrimide, on membrane transport and binding of GABA and taurine in the mouse cerebrum. | 1987 Jan |
|
Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients. | 1987 Mar-Apr |
|
A controlled study with taltrimide and sodium valproate: valproate effective in partial epilepsy. | 1990 Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3143554
in daily doses of 1 and 2 g for 2 weeks with an interval of 2.5 months in 2 phase I clinical trials to 9 drug-resistant epileptic patients.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5342
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107479
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
100000083210
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
NQ74U9QR5D
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
C72857
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
SUB10817MIG
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
71248
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
81428-04-8
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY | |||
|
C046932
Created by
admin on Sat Dec 16 17:45:21 GMT 2023 , Edited by admin on Sat Dec 16 17:45:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY